Company Overview and News
Delta Air Lines has entered into a multi-year contract with Airbus to continue using the Skywise open-data platform and related predictive maintenance services. The airline will expand the use of the tool to its A320 and A330 fleets – comprising around 400 aircraft – to track and analyse their operations and performance data and assess failure probabilities in order to anticipate maintenance tasks.
Netflix – Netflix reported quarterly profit of 89 cents per share, easily beating the consensus estimate of 68 cents a share. Revenue was in line with Street forecasts, and the important metric of net subscriber additions was well above analysts' expectations for the video streaming service.
HD XKE GEC GE DB GNE DAL
Airline stocks are getting a big boost in premarket trade Wednesday, as better-than-expected earnings from UnitedContinental Holdings Inc. UAL, +5.66% in the wake of Delta Air Lines Inc.'s DAL, +2.52% upbeat results last week, provided a bout of optimism for the host of companies reporting next week. United's stock soared 5.7% ahead of the open, after reporting results late Tuesday, while Delta shares surged 3.
AAL SAVE DAL ALK
United Airlines posted a forecast-beating rise in third-quarter profit on Tuesday and raised its 2018 forecast for the third time this year, lifted by its strategy to add flights at three mid-continent U.S. hubs: Chicago, Denver and Houston.
U.S. stock futures fell on Wednesday, a day after Wall Street's strongest rally in seven months, as investors were disappointed with IBM's results and remained cautious ahead of the minutes of Federal Reserve's latest meeting.
LRCX ASML DAL
2018-10-16 investorplace - 2
The stock market has been a rough ride these past few weeks. Coming into October, all was fine as we recovered from the early February declines and went on to make new all-time highs. But with the Nasdaq falling some 10% in 10 trading sessions, investors are looking for safer stocks and that usually means dividend stocks.
BAC TJX AOS AAPL TSLA SBUX NFLX MSFT BA DAL
2018-10-16 zacks - 1
In the past week, Delta Air Lines, Inc. (DAL - Free Report) kick-started the third-quarter earnings season for the airline space. This Atlanta, GA-based carrier reported better-than-expected earnings per share but lower-than-expected revenues. Despite a 35% rise in adjusted fuel bill, the bottom line increased on a year-over-year basis in the reported quarter.
HA JBLU ALK DAL
According to the 2018 edition of the Stock Trader’s Almanac, October has been a “great” time to buy. Once ranked last in terms of stock performance, the 10th month has delivered relatively average returns since 1950. What makes it so attractive is that it’s followed by November and December, historically among the very best months for stocks. We’re also entering the three most bullish quarters of the four-year presidential cycle, based on 120 years of stock market data.
AMZN AAPL NFLX DAL
Even during the healthiest bull markets, there will be down days … weeks … even months. But don’t let that send you off course. Sure, if a stock has little prospect of an uptime, it’s a good idea to get out — and the sooner the better. This could be because of a fundamental shift in the stock’s prospects like a long-term decline in demand trends. However that isn’t the case with the stocks below.
HD DB AMZN PYPL ADSK DAL
SAO PAULO, Oct 15 (Reuters) - Brazilian airline Gol Linhas Aéreas Inteligentes SA on Monday announced a plan to buy out minority shareholders in its loyalty program Smiles Fidelidade SA for an undisclosed price, battering the unit’s shares and prompting regulatory scrutiny.
ACDVF DAL AC
SAO PAULO, Oct 15 (Reuters) - Brazil’s Gol Linhas Aéreas Inteligentes SA said on Monday that it plans to buy out minority shareholders in loyalty program Smiles Fidelidade SA for an undisclosed price, sending Smiles’ shares 34 percent lower.
ACDVF DAL AC
Delta Air Lines’ record third-quarter (Q3) revenues received a notable boost from the carrier’s transatlantic performance, with key growth metrics for the region leading the carrier’s network. “Core demand in the transatlantic remains incredibly strong,” President Glen Hauenstein said on the carrier’s recent Q3 earnings call. “And we’re looking for RASM through the winter to be quite positive, despite the fact that there is a lot of capacity .
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to DAL / Delta Air Lines, Inc. on message board site Silicon Investor.
as of ET